Compare UMC & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMC | ZTS |
|---|---|---|
| Founded | 1980 | 1952 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3B | 31.2B |
| IPO Year | 1997 | 2012 |
| Metric | UMC | ZTS |
|---|---|---|
| Price | $18.23 | $81.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $154.18 |
| AVG Volume (30 Days) | ★ 13.7M | 7.7M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.92% | 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 1.42 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $11.22 | $5.63 |
| Revenue Next Year | $10.15 | $4.77 |
| P/E Ratio | ★ $18.95 | $56.30 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $6.56 | $73.82 |
| 52 Week High | $18.45 | $172.23 |
| Indicator | UMC | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 81.76 | 28.89 |
| Support Level | $7.03 | $73.82 |
| Resistance Level | N/A | $129.32 |
| Average True Range (ATR) | 0.69 | 3.79 |
| MACD | 0.16 | -0.25 |
| Stochastic Oscillator | 94.93 | 18.07 |
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the US, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Intel, Broadcom, Novatek, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 19,000 people as of February 2025.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.